[The treatment of hot flashes due to menopause. Comparative study of two drugs (author's transl)].
The efficacy of veralipride, a new non-hormonal treatment for the treatment of menopausal symptoms, was evaluated following a randomised comparative study with a commonly used non-hormonal drug, bêta-alanine. Two groups of patients between 53 and 59 years received, one veralipride (22) at a dose of 100 mg/day for 20 days, the other beta-alanine (21) during the same period. 14 patients noted an improvement in their hot flushes while receiving veralipride as against 4 receiving beta-alanine. The superiority of veralipride was quite significant (P less than 0.01). Both products were well tolerated.
D000328:Adult; D000409:Alanine / Q000627:therapeutic use*; D002979:Climacteric / Q000187:drug effects*; D005260:Female; D006801:Humans; D008593:Menopause; D008875:Middle Aged; D013469:Sulpiride / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015091:beta-Alanine / Q000009:adverse effects / Q000627:therapeutic use*
D015091:beta-Alanine; D013469:Sulpiride; D000409:Alanine; C027429:veralipride
Le traitement des bouffées de chaleur de la ménopause. Etude comparative de deux médicaments.